JP2019513755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513755A5 JP2019513755A5 JP2018552900A JP2018552900A JP2019513755A5 JP 2019513755 A5 JP2019513755 A5 JP 2019513755A5 JP 2018552900 A JP2018552900 A JP 2018552900A JP 2018552900 A JP2018552900 A JP 2018552900A JP 2019513755 A5 JP2019513755 A5 JP 2019513755A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- oxy
- fluoro
- hexane
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3,4-difluorophenyl Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- KPNFHMCCBRGOKU-UHFFFAOYSA-N bicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound C1CCC2C(C(=O)O)C21 KPNFHMCCBRGOKU-UHFFFAOYSA-N 0.000 claims 13
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 9
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- BSUBXBXNFNRXLH-VLBIBGDSSA-N (1R,2R,3R,5R,6R)-2-[(1S)-1-(adamantane-1-carbonyloxy)ethoxy]carbonyl-2-amino-3-[(3,4-difluorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound C[C@H](OC(=O)[C@@]1(N)[C@H]2[C@@H](C[C@H]1OCc1ccc(F)c(F)c1)[C@]2(F)C(O)=O)OC(=O)C12CC3CC(CC(C3)C1)C2 BSUBXBXNFNRXLH-VLBIBGDSSA-N 0.000 claims 3
- FXAUGNLOKIBSSI-QPNZBKOUSA-N (1R,2R,3R,5R,6R)-2-amino-6-fluoro-2-[(1R)-1-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxycarbonyloxyethoxy]carbonyl-3-propoxybicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound CCCO[C@@H]1C[C@@H]2[C@@H]([C@@]2(F)C(O)=O)[C@]1(N)C(=O)O[C@@H](C)OC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C FXAUGNLOKIBSSI-QPNZBKOUSA-N 0.000 claims 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- SNXOMRRYFYTWCF-RFVFKLTOSA-N (1R,2R,3R,5R,6R)-2-(adamantane-1-carbonyloxymethoxycarbonyl)-2-amino-3-[(3,4-difluorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound N[C@@]1([C@H]2[C@@H](C[C@H]1OCc1ccc(F)c(F)c1)[C@]2(F)C(O)=O)C(=O)OCOC(=O)C12CC3CC(CC(C3)C1)C2 SNXOMRRYFYTWCF-RFVFKLTOSA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- SUMBAGQHELWXAH-VGRWTXIISA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OC1CCCC1)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OC1CCCC1)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 SUMBAGQHELWXAH-VGRWTXIISA-N 0.000 claims 2
- AYTGZRUNQPAGMB-AHGQKZNCSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)C(F)(F)F)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)C(F)(F)F)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 AYTGZRUNQPAGMB-AHGQKZNCSA-N 0.000 claims 2
- LDYPAZNOEPBADX-VUXCPXMOSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(=O)C12CC3CC(CC(C1)C3)C2 LDYPAZNOEPBADX-VUXCPXMOSA-N 0.000 claims 2
- MVWQVJMUJVPRTG-NJZZVLKSSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=NC(=CC=C1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=NC(=CC=C1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 MVWQVJMUJVPRTG-NJZZVLKSSA-N 0.000 claims 2
- GTGBFHLAGTYUFQ-YDEGJAPISA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=NC=C(C=C1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=NC=C(C=C1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 GTGBFHLAGTYUFQ-YDEGJAPISA-N 0.000 claims 2
- GQZRDISSNBHANR-BIAYIWCMSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC=1C=NC(=CC=1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC=1C=NC(=CC=1)Cl)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 GQZRDISSNBHANR-BIAYIWCMSA-N 0.000 claims 2
- NRUGHQBPAUDUHP-USZDCDMHSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCCC(C)C)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCCC(C)C)(C(=O)O)F)C(=O)O[C@@H](C)OC(=O)C12CC3CC(CC(C1)C3)C2 NRUGHQBPAUDUHP-USZDCDMHSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FXAUGNLOKIBSSI-IOEMREFESA-N (1R,2R,3R,5R,6R)-2-amino-6-fluoro-2-[1-[(1S,2R,5S)-5-methyl-2-propan-2-ylcyclohexyl]oxycarbonyloxyethoxycarbonyl]-3-propoxybicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCCC)(C(=O)O)F)C(=O)OC(C)OC(=O)O[C@@H]1[C@H](CC[C@@H](C1)C)C(C)C FXAUGNLOKIBSSI-IOEMREFESA-N 0.000 claims 1
- PAXOWJOGPVZJKG-MBQZEHINSA-N (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-propoxy-2-[1-[[(1S,2R,4S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]oxycarbonyloxy]ethoxycarbonyl]bicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCCC)(C(=O)O)F)C(=O)OC(C)OC(=O)O[C@H]1[C@]2(CC[C@@H](C1)C2(C)C)C PAXOWJOGPVZJKG-MBQZEHINSA-N 0.000 claims 1
- UWXZAQRGPGNMCW-JGFHSLCKSA-N (1S,2R,3R,5R,6S)-2-[(1S)-1-(adamantane-1-carbonyloxy)ethoxy]carbonyl-2-amino-3-[(4-fluorophenyl)methoxy]bicyclo[3.1.0]hexane-6-carboxylic acid Chemical compound C[C@H](OC(=O)[C@@]1(N)[C@H]2[C@@H](C[C@H]1OCc1ccc(F)cc1)[C@@H]2C(O)=O)OC(=O)C12CC3CC(CC(C3)C1)C2 UWXZAQRGPGNMCW-JGFHSLCKSA-N 0.000 claims 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- LADLKLQNZRWJGI-BZVMJTILSA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(=O)C1CCCCC1 Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(=O)C1CCCCC1 LADLKLQNZRWJGI-BZVMJTILSA-N 0.000 claims 1
- BBDFLRQFEOWZRR-UGGHSASASA-N N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(C(C)(C)C)=O Chemical compound N[C@@]1([C@@H]2[C@]([C@@H]2C[C@H]1OCC1=CC=C(C=C1)F)(C(=O)O)F)C(=O)OCOC(C(C)(C)C)=O BBDFLRQFEOWZRR-UGGHSASASA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016083147 | 2016-04-18 | ||
| JP2016083147 | 2016-04-18 | ||
| PCT/JP2017/016125 WO2017183734A1 (en) | 2016-04-18 | 2017-04-18 | Prodrug of amino acid derivative |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212361A Division JP2021063095A (ja) | 2016-04-18 | 2020-12-22 | アミノ酸誘導体のプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513755A JP2019513755A (ja) | 2019-05-30 |
| JP2019513755A5 true JP2019513755A5 (cg-RX-API-DMAC7.html) | 2019-11-07 |
| JP7045321B2 JP7045321B2 (ja) | 2022-03-31 |
Family
ID=58737797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552900A Active JP7045321B2 (ja) | 2016-04-18 | 2017-04-18 | アミノ酸誘導体のプロドラッグ |
| JP2020212361A Withdrawn JP2021063095A (ja) | 2016-04-18 | 2020-12-22 | アミノ酸誘導体のプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212361A Withdrawn JP2021063095A (ja) | 2016-04-18 | 2020-12-22 | アミノ酸誘導体のプロドラッグ |
Country Status (29)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2886442T3 (es) * | 2016-04-18 | 2021-12-20 | Taisho Pharmaceutical Co Ltd | Profármaco de derivado de aminoácido |
| JP7314494B2 (ja) * | 2017-10-17 | 2023-07-26 | 大正製薬株式会社 | アミノ酸誘導体のプロドラッグを含有する医薬 |
| ES2970042T3 (es) * | 2018-04-24 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos con actividad inhibidora de la maduración del VIH |
| CN109180712B (zh) * | 2018-08-08 | 2020-12-25 | 南京医科大学 | 一类2-茨醇的芳基硼酸酯衍生物及其应用 |
| CN108948077B (zh) * | 2018-08-09 | 2020-10-13 | 东华理工大学 | 一种α-磷酰化的α-氨基酸酯类化合物及其合成方法 |
| WO2022114135A1 (ja) * | 2020-11-26 | 2022-06-02 | 大正製薬株式会社 | アミノ酸誘導体の結晶形及びその製造方法 |
| CN112409443B (zh) * | 2021-01-25 | 2021-04-27 | 潍坊科技学院 | 一种脯氨酸茨醇衍生物及其制备方法和在制备治疗心脑血管类疾病的药物中的应用 |
| CN114805104A (zh) * | 2021-01-29 | 2022-07-29 | 南京宁丹新药技术有限公司 | 一类氨基水杨酸类衍生物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1463713A1 (en) | 2001-11-23 | 2004-10-06 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| NZ533699A (en) * | 2001-12-27 | 2006-05-26 | Taisho Pharmaceutical Co Ltd | 6-fluorobicyclo[3.1.0]hexane derivatives |
| DK2123630T3 (da) | 2003-06-26 | 2012-10-22 | Braincells Inc | 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat |
| TW201124372A (en) | 2009-11-19 | 2011-07-16 | Taisho Pharmaceutical Co Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| US9056844B2 (en) * | 2010-11-18 | 2015-06-16 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
| WO2013062680A1 (en) | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| EP2857385B1 (en) * | 2012-06-01 | 2017-08-02 | Taisho Pharmaceutical Co., Ltd. | Prodrug of fluorine-containing amino acid |
| US20150119345A1 (en) | 2013-10-29 | 2015-04-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of gastrointestinal infections |
| ES2886442T3 (es) * | 2016-04-18 | 2021-12-20 | Taisho Pharmaceutical Co Ltd | Profármaco de derivado de aminoácido |
-
2017
- 2017-04-18 ES ES17724459T patent/ES2886442T3/es active Active
- 2017-04-18 EP EP17724459.7A patent/EP3445743B1/en active Active
- 2017-04-18 LT LTEPPCT/JP2017/016125T patent/LT3445743T/lt unknown
- 2017-04-18 MY MYPI2018703815A patent/MY195208A/en unknown
- 2017-04-18 NZ NZ747061A patent/NZ747061A/en unknown
- 2017-04-18 HU HUE17724459A patent/HUE056046T2/hu unknown
- 2017-04-18 RS RS20211289A patent/RS62515B1/sr unknown
- 2017-04-18 AU AU2017254266A patent/AU2017254266B2/en active Active
- 2017-04-18 SG SG11201808387PA patent/SG11201808387PA/en unknown
- 2017-04-18 PT PT177244597T patent/PT3445743T/pt unknown
- 2017-04-18 SI SI201730877T patent/SI3445743T1/sl unknown
- 2017-04-18 TW TW106112946A patent/TWI738767B/zh active
- 2017-04-18 KR KR1020187029353A patent/KR102444718B1/ko active Active
- 2017-04-18 HR HRP20211277TT patent/HRP20211277T1/hr unknown
- 2017-04-18 PL PL17724459T patent/PL3445743T3/pl unknown
- 2017-04-18 MX MX2018012442A patent/MX379567B/es unknown
- 2017-04-18 JP JP2018552900A patent/JP7045321B2/ja active Active
- 2017-04-18 US US15/765,903 patent/US10464884B2/en active Active
- 2017-04-18 CN CN201780024360.7A patent/CN109071418B/zh active Active
- 2017-04-18 SM SM20210601T patent/SMT202100601T1/it unknown
- 2017-04-18 RU RU2018140250A patent/RU2739318C2/ru active
- 2017-04-18 DK DK17724459.7T patent/DK3445743T3/da active
- 2017-04-18 WO PCT/JP2017/016125 patent/WO2017183734A1/en not_active Ceased
- 2017-04-18 CA CA3019097A patent/CA3019097C/en active Active
- 2017-04-18 SG SG10202006019YA patent/SG10202006019YA/en unknown
- 2017-04-18 BR BR112018069959-4A patent/BR112018069959B1/pt active IP Right Grant
-
2018
- 2018-09-27 ZA ZA2018/06444A patent/ZA201806444B/en unknown
- 2018-10-09 IL IL262233A patent/IL262233B/en unknown
- 2018-10-16 PH PH12018502211A patent/PH12018502211A1/en unknown
-
2019
- 2019-07-15 US US16/511,349 patent/US10689327B2/en active Active
-
2020
- 2020-12-22 JP JP2020212361A patent/JP2021063095A/ja not_active Withdrawn
-
2021
- 2021-10-08 CY CY20211100876T patent/CY1124574T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513755A5 (cg-RX-API-DMAC7.html) | ||
| RU2018140250A (ru) | Пролекарство производного аминокислоты | |
| JP2014511892A5 (cg-RX-API-DMAC7.html) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2014511891A5 (cg-RX-API-DMAC7.html) | ||
| JP2014051526A5 (cg-RX-API-DMAC7.html) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2010540509A5 (cg-RX-API-DMAC7.html) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2011509309A5 (cg-RX-API-DMAC7.html) | ||
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| JP2014507455A5 (cg-RX-API-DMAC7.html) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| JP2015505296A5 (cg-RX-API-DMAC7.html) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2014511893A5 (cg-RX-API-DMAC7.html) | ||
| RU2016134751A (ru) | Соединения | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| RU2015143610A (ru) | Лечение катаплексии | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| JP2015500842A5 (cg-RX-API-DMAC7.html) | ||
| RU2017107521A (ru) | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar | |
| RU2016132858A (ru) | Производные фторнафтила | |
| JP2016504992A5 (cg-RX-API-DMAC7.html) |